Prevention of Thromboembolic Events in Patients with COVID-19
Open Access
- 4 July 2021
- journal article
- letter
- Published by Georg Thieme Verlag KG in TH Open
- Vol. 05 (03) , e415-e419
Abstract
Background: COVID-19 has developed into a global pandemic with respiratory compromise and systemic coagulopathy causing significant morbidity and mortality. Methods: A retrospective analysis was performed on all COVID-19 patients hospitalized between March and June 2020. Findings: Of 1265 COVID-19 positive hospitalized patients identified, 138 (10.9%) had a thromboembolism. Mortality rate in COVID-19 patients with thrombosis was 31.9%, significantly higher than COVID-19 patients who did not have thrombosis 10% (p<0.0001). The incidence of thrombosis was significantly less in those who received steroids at 14% as compared to other COVID-19 therapies: tocilizumab 25% (p=0.0031), hydroxychloroquine 42% (p<0.0001), and remdesivir 72% (p<0.0001). There was no difference in mortality in patients who had prophylactic enoxaparin 40.5% than therapeutic enoxaparin 51.7% (p= 0.3491). Adjusting for demographics, a logistics model showed no mortality difference in patients who had either dosing of anticoagulation (p=0.5810). The bleeding rate was 12.3%, significantly higher than reported bleeding rates for hospitalized nonCOVID-19 patients on anticoagulants at 7.2% (p<0.05). Interpretation: Our study shows the incidence of thrombosis in hospitalized COVID-19 patients was higher than the general population. The lowest incidence of thrombosis occurred in COVID-19 patients who received steroids. There was no mortality difference in patients who received prophylactic versus therapeutic anticoagulation prior to thrombosis, but there was a high incidence of bleeding events. Funding: No outside funding was used Received: 19 February 2021 Accepted after revision: 27 July 2021 Publication Date: 02 August 2021 (online) © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyKeywords
This publication has 10 references indexed in Scilit:
- Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019Chest, 2021
- Dexamethasone in Hospitalized Patients with Covid-19New England Journal of Medicine, 2021
- American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19Blood Advances, 2021
- Current Overview on Hypercoagulability in COVID-19American Journal of Cardiovascular Drugs, 2020
- COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infectionBlood, 2020
- Incidence of thrombotic complications in critically ill ICU patients with COVID-19Thrombosis Research, 2020
- Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forumJournal of Thrombosis and Thrombolysis, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Risk of bleeding in hospitalized patients on anticoagulant therapy: Prevalence and potential risk factorsEuropean Journal of Internal Medicine, 2019
- Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxisIntensive Care Medicine, 2013